{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:29:35Z","timestamp":1788827375619,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Funding was obtained from Roche Diagnostics for the study and biological tests"},{"name":"Funding from Roche Diagnostics for the study and biological tests"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23007-w","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:04:08Z","timestamp":1762787048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["sFlt-1\/PlGF ratio use does not reduce hospitalisation duration in suspected preeclampsia: the PRECOG study, a multicentre randomised trial"],"prefix":"10.1038","volume":"15","author":[{"given":"J.","family":"Sibiude","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lecarpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Perrotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huissoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Piver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Bondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Buth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guibourdenche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tsatsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"10297","key":"23007_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","volume":"398","author":"LC Chappell","year":"2021","unstructured":"Chappell, L. C., Cluver, C. A., Kingdom, J. & Tong, S. Pre-eclampsia. Lancet 398 (10297), 341\u2013354 (2021).","journal-title":"Lancet"},{"issue":"7","key":"23007_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl. J. Med. 350 (7), 672\u2013683 (2004).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"23007_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl. J. Med. 374 (1), 13\u201322 (2016).","journal-title":"N Engl. J. Med."},{"issue":"7","key":"23007_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","volume":"125","author":"S Rana","year":"2012","unstructured":"Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125 (7), 911\u2013919 (2012).","journal-title":"Circulation"},{"issue":"1","key":"23007_CR5","first-page":"164","volume":"74","author":"X Bian","year":"2019","unstructured":"Bian, X. et al. Short-Term prediction of adverse outcomes using the sFlt-1 (Soluble fms-Like tyrosine kinase 1)\/PlGF (Placental growth Factor) ratio in Asian women with suspected preeclampsia. Hypertens. Dallas Tex. 1979. 74 (1), 164\u2013172 (2019).","journal-title":"Hypertens. Dallas Tex. 1979"},{"key":"23007_CR6","doi-asserted-by":"crossref","unstructured":"Cerdeira, A. S. et al. Randomized interventional study on prediction of Preeclampsia\/Eclampsia in women with suspected preeclampsia: INSPIRE. Hypertens Dallas Tex 1979. 74(4):983\u2013990 (2019).","DOI":"10.1161\/HYPERTENSIONAHA.119.12739"},{"issue":"5","key":"23007_CR7","first-page":"827","volume":"82","author":"ACM Kluivers","year":"2025","unstructured":"Kluivers, A. C. M. et al. PRERISK study: A randomized controlled trial evaluating a sFlt-1\/PlGF-Based calculator for preeclampsia hospitalization. Hypertension 82 (5), 827\u2013838 (2025).","journal-title":"Hypertension"},{"issue":"10183","key":"23007_CR8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","volume":"393","author":"KE Duhig","year":"2019","unstructured":"Duhig, K. E. et al. PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 393 (10183), 1807\u20131818 (2019).","journal-title":"Lancet"},{"key":"23007_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1136\/bmj.n1857","volume":"374","author":"D Hayes-Ryan","year":"2021","unstructured":"Hayes-Ryan, D. et al. Placental growth factor in assessment of women with suspected preeclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland). BMJ 374, 1857 (2021).","journal-title":"BMJ"},{"issue":"10","key":"23007_CR10","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1161\/HYPERTENSIONAHA.122.20361","volume":"80","author":"L De Oliveira","year":"2023","unstructured":"De Oliveira, L. et al. PREPARE trial group. PREPARE: A Stepped-Wedge Cluster-Randomized trial to evaluate whether risk stratification can reduce preterm deliveries among patients with suspected or confirmed preterm preeclampsia. Hypertension 80 (10), 2017\u20132028 (2023).","journal-title":"Hypertension"},{"key":"23007_CR11","unstructured":"NICE. PLGF-based testing to help diagnose suspected preterm pre-eclampsia. Diagnostics guidance [DG49] [Internet] 27\/07\/2022. Available on: https:\/\/www.nice.org.uk\/guidance\/dg49."},{"issue":"1","key":"23007_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/AOG.0000000000003018","volume":"133","author":"ACOG Practice Bulletin No","year":"2019","unstructured":"ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet. Gynecol. 133 (1), 1. https:\/\/doi.org\/10.1097\/AOG.0000000000003018 (2019).","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"23007_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jogc.2022.03.002","volume":"44","author":"LA Magee","year":"2022","unstructured":"Magee, L. A. et al. Guideline 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J. Obstet. Gynaecol. Can. 44 (5), 547\u20135710. https:\/\/doi.org\/10.1016\/j.jogc.2022.03.002 (2022).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"23007_CR14","unstructured":"Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aoteroa New Zealand: a clinical practice guideline [Internet]. Ministry of Health NZ. Available on: (2022). https:\/\/www.health.govt.nz\/publication\/diagnosis-and-treatment-hypertension-and-pre-eclampsia-pregnancy-new-zealand-clinical- practice."},{"issue":"11","key":"23007_CR15","doi-asserted-by":"publisher","first-page":"e50208","DOI":"10.1371\/journal.pone.0050208","volume":"7","author":"J Sibiude","year":"2012","unstructured":"Sibiude, J. et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One. 7 (11), e50208 (2012).","journal-title":"PLoS One"},{"key":"23007_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","volume":"27","author":"LA Magee","year":"2022","unstructured":"Magee, L. A. et al. The 2021 international society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 27, 148\u2013169 (2022).","journal-title":"Pregnancy Hypertens."},{"issue":"5","key":"23007_CR17","doi-asserted-by":"publisher","first-page":"e0156013","DOI":"10.1371\/journal.pone.0156013","volume":"11","author":"E Klein","year":"2016","unstructured":"Klein, E. et al. Influence of the sFlt-1\/PlGF ratio on clinical Decision-Making in women with suspected preeclampsia. PLoS One. 11 (5), e0156013 (2016).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:04:10Z","timestamp":1762787050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23007"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23007-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were independent of the funders. Disclosures V. Tsatsaris is a member of the advisory board and received speaker fees from Roche Diagnostics, Alexion and Sanofi. NW, OM, CH, FP, EP declare participation as expert and speaker activities for Roche Diagnostics France. JG received fees as expert in biochemical endocrinology to advisory boards from Merck. JS, EL, DM, GK, MR, FPB, VB and GM declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39299"}}